

[View this email in your browser](#)



Clarity. Insights. Expertise.

## Clinical Bulletin

The U.S. Food and Drug Administration (FDA) approved Coherus BioSciences' Cimerli™ (ranibizumab-eqrn) injection on Aug. 2, 2022. As the first interchangeable biosimilar for Lucentis® (ranibizumab) to be approved in the United States, it will have one year of exclusivity from its launch date before another interchangeable Lucentis biosimilar can enter the market. Both products are indicated for intravitreal (into the eye) injections for treating neovascular (wet) age-related macular degeneration (nAMD), macular edema after retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR) and myopic choroidal neovascularization (mCNV). In general, treatments for the conditions are administered once a month, but dosing intervals can be longer for some patients. Because they are injected into the eyes by specially trained healthcare providers in a sterile medical facility, coverage often falls under medical benefits. Specialty pharmacies also dispense ophthalmic VEGF inhibitors, however. Its release is scheduled to start early in October, but pricing and distribution channels have not yet been announced. Prescribing information for Cimerli is [here](#).